Human Mutation Journal Citation Rate 2026
1059-7794
eISSN 1098-1004
Wiley
US
Q3 Quartile Verified Publisher
About Human Mutation
Human Mutation (HM) is a peer-reviewed academic journal covering Cancer Genomics and Diagnostics and Genomic variations and chromosomal abnormalities, published by Wiley in US, catalogued under ISSN 1059-7794 (e-ISSN 1098-1004). As of 2026, it has a 2025 2-Year Citation Rate (OpenAlex) of 0.89 (Q3 quartile) — the average number of citations its recent articles received over a two-year window, computed from OpenAlex open citation data, not the Clarivate (JCR) Impact Factor. It operates a subscription model (APC ~$2300 USD). OpenAlex records 8,117 works and 363,802 citations, with an h-index of 219.
Human Mutation Citation Rate 2026 — In Context
Human Mutation has a 2025 2-Year Citation Rate (OpenAlex) of 0.89, placing it in the Q3 quartile within the Cancer Genomics and Diagnostics research area. This is the average number of citations the journal's recent articles received over a two-year window, computed from OpenAlex open citation data — not the Clarivate (JCR) Journal Impact Factor.
Human Mutation operates a subscription-based publishing model — readers access articles through institutional subscriptions or pay-per-view.
Researchers looking to publish in Human Mutation should review the journal's submission tips and verify the latest indexing status against Scopus, DOAJ, and Web of Science using our indexing tracker. To compare Human Mutation against similar journals in the field, use our journal comparison tool.
Submission Tips for Human Mutation
- Budget $2300 for the Article Processing Charge. Check if your institution or funder covers OA fees.
- This journal covers Cancer Genomics and Diagnostics, Genomic variations and chromosomal abnormalities, Genomics and Rare Diseases. Ensure your manuscript aligns with these scope areas to avoid desk rejection.
How Human Mutation Compares
Compared against 64 journals in the same research areas.
| ISSN (Print) | 1059-7794 |
|---|---|
| ISSN (Online) | 1098-1004 |
| Publisher | Wiley |
| Country | United States |
| APC / Cost | $2300 USD |
In-depth profile & metrics
Human Mutation is published by Wiley and based in United States. It runs on a subscription or hybrid model with an article-processing charge of USD 2300.
In our subject taxonomy, Human Mutation is classified under Cancer Genomics and Diagnostics, Genomic variations and chromosomal abnormalities, Genomics and Rare Diseases and Metabolism and Genetic Disorders.
Human Mutation is indexed in OpenAlex. OpenAlex tracking provides an open, citable record of its output even where commercial indexing is absent.
Its most recent citation rate stands at 0.888.
Research Areas
Links
Continue on JournalsHub
Put what you just read into practice with these free tools.
Frequently Asked Questions about Human Mutation
Live Indexing Status
Updated April 2026Track real-time indexing metrics to ensure this journal meets your academic requirements.
Citation Rate
Historical Trend
Initial data points onlyCitation Rate by Year
| Year | Value | Source |
|---|---|---|
| 2025 | 0.888 | 2-Year Mean Citedness (OpenAlex) |
Metrics are sourced from OpenAlex, DOAJ and Scopus and reflect the latest data we hold. The headline figure is a 2-year citation rate (OpenAlex), not a Clarivate Impact Factor. Always verify against the journal's official site before relying on it. See our Methodology or report a correction.
Compare Journals
Compare Human Mutation against similar publications in its field:
Related Journals in Your Field
-
Cell Reports Elsevier IF 64.50
-
Cell Death and Disease Springer Nature IF 64.50
-
Cancer Cell Elsevier IF 64.50
-
DNA and Cell Biology Mary Ann Liebert IF 64.50
-
Frontiers in Cell and Developmental Biology Frontiers Media SA IF 64.50
Explore More Journals
Metadata
Last updated: Apr 24, 2026
Updated by: openalex_bulk
OpenAlex ID: S98809561
Get weekly updates for Cancer Genomics and Diagnostics journals
Free. Monday morning. New citation rates, CFPs, indexing alerts, predatory watch list. One-click unsubscribe.